Background: Early tumor shrinkage (ETS) and depth of response (DoR) predict overall survival (OS) in first-line trials of chemotherapy ± anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev.
introduction
Achieving tumor shrinkage may be a clinically relevant objective in the treatment of metastatic colorectal cancer (mCRC). In fact, not only this may allow the secondary resection of metastatic lesions [1] , thus providing a chance of cure even in the metastatic setting for a subgroup of patients, but also, in the case of aggressive diseases with high tumor load, this may improve symptoms or delay their occurrence. Moreover, in the pretargeted era, a correlation of response to the first-line treatment with overall survival (OS) was shown [2] .
The ability of a treatment regimen in inducing tumor shrinkage is now estimated by the Response Evaluation Criteria in Solid Tumors (RECIST) response rate [3, 4] . Size-based RECIST defines responders versus non-responders by adopting a 30% reduction in the sum of the longest diameters of target lesions as cutoff value.
More recently, two new concepts have been developed in order to better catch the ability of treatment regimens in determining a rapid and remarkable shrinkage: early tumor shrinkage (ETS) and depth of response (DoR).
The post-hoc analysis of two randomized trials, CRYSTAL and OPUS, evaluating the addition of cetuximab to first-line FOLFIRI and FOLFOX, respectively, showed that the anti-EGFR monoclonal antibody (MoAb) significantly increases the percentage of patients achieving tumor shrinkage at the first computed tomography (CT) scan evaluation (i.e. after 8 weeks from treatment start). Based on a time-dependent receiver operating characteristics approach, a 20% reduction in the sum of the longest diameters of target lesions was identified as the optimal cutoff to discriminate early responders versus non-early responders. A significant correlation of the ETS with both progressionfree survival (PFS) and OS was reported and was more evident in the chemotherapy plus cetuximab group, thus suggesting a potential role of ETS as a predictive marker of benefit from the anti-EGFR MoAb [5] . The addition of panitumumab to firstline FOLFOX was also able to increase the percentage of patients achieving an ETS ≥30% and ETS was associated with longer survival [6] .
With regard to the DoR, defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir, compared with baseline, the post-hoc analysis of the CRYSTAL and OPUS trials evidenced that the addition of cetuximab significantly improves the DoR. Moreover, achieving a deeper response correlated with longer OS and post-progression survival (PPS) [7] .
Taken together, these results underline the impact of active upfront regimens on long-term outcome and evidence the potential usefulness of these measures as valuable predictors of survival, to be further investigated in clinical trials.
The phase III TRIBE trial recently compared first-line FOLFOXIRI plus bevacizumab (bev) with FOLFIRI plus bev in unresectable mCRC patients, demonstrating that the intensification of the chemotherapy backbone increases PFS [ primary end point, 12.1 versus 9.7 months, hazard ratio (HR) 0.75 (0.62-0.90), P = 0.003], RECIST response rate (65% versus 53%, P = 0.006) and OS [31.0 versus 25.8 months, HR: 0.79 (0.63-1.00), P = 0.054] [8] . CT scans from patients enrolled in TRIBE trial were re-evaluated in order to investigate potential differences between the two arms in terms of ETS and DoR and to assess their correlation with long-term outcome. The predictive accuracy of response measures (RECIST response, ETS and DoR) with respect to PFS, PPS and OS was also evaluated.
patients and methods
the TRIBE study TRIBE (TRIplet plus BEvacizumab) was a multicenter, randomized, phase III trial conducted by the Italian Cooperative GONO (Gruppo Oncologico Nord Ovest) group (NCT00719797). Five-hundred eight unresectable mCRC patients, untreated for the metastatic disease were randomized to receive FOLFOXIRI plus bev and FOLFIRI plus bev as initial treatment. Patients received up to 12 cycles of induction treatment according to the randomization assignment, followed by maintenance with 5-fluoruracil and bev until the evidence of disease progression in both arms. The primary end point of the trial was PFS. RECIST response was a prespecified secondary end point. The trial was conducted in 34 Italian Oncology Units and was approved by the local ethics committee for each participating site.
assessments
Tumor assessment was carried out every 8 weeks until the evidence of disease progression by means of CT scan. Treatments' activity was assessed according to RECIST v1.0. ETS was defined as the relative change in the sum of longest diameters of RECIST target lesions at week 8 compared with baseline. DoR was defined as the relative change in the sum of longest diameters of RECIST target lesions at the nadir, in the absence of new lesions or progression of non-target lesions, when compared with baseline. Both ETS and DoR were negative for increasing tumor load.
statistical analysis
All analyses were based on a landmark approach, excluding from the intention-to-treat population of the TRIBE trial all patients with an observation time lower than 4 months. This landmark coincides with the time of the second CT scan reassessment, which is the earliest time to confirm tumor response according to RECIST v1.0. The distributions of the post-randomization prognostic factors in the two treatment arms were compared with the χ 2 test for heterogeneity or the Kruskal-Wallis test.
ETS, DoR and RECIST response were investigated for their prognostic impact on PFS, PPS and OS. ETS was treated either as continuous or binary (≥20% versus <20%) variable. DoR was evaluated either as continuous or ordinal variable, with five levels based on quintile distribution. Each patient was classified as responder or not responder at the landmark limit according to the RECIST v1.0 evaluation (CR + PR versus other). PFS was defined as the time interval between the landmark limit and the date of disease progression or death. PPS was defined as the time between the first documented disease progression and death, whatever the cause. OS was computed as the interval between the landmark limit and death for any cause. The distributions of PFS, PPS and OS were estimated using the Kaplan-Meier method and compared with the log-rank test. HRs with 95% confidence intervals (CIs) were calculated with the Cox proportional hazards model. Likelihood ratio test was used to test the statistical significance of all coefficients. The optimal cut point value determination was carried out according to Contal and O'Quigley [9] . Predictive discrimination ability of the prognostic models was evaluated by means of the Pencina C-index [10] . No adjustment for multiplicity was carried out. LB carried out statistical analyses using SAS version 9.2 (SAS Institute, Cary, NC) and was blind to clinical data. results patients Four-hundred forty-one (86.8%) of 508 randomized patients were included in the present analysis (assessable population, Figure 1 ). Baseline characteristics did not significantly differ between the intention-to-treat and the assessable population (supplementary Table S1 , available at Annals of Oncology online). In the assessable population, at a median follow-up of 28.3 months, not including the first 4 months after randomization (landmark), median PFS was 9.2 months in the FOLFOXIRI plus bev arm and 7. response measurements according to treatment arm
As reported in Table 1 , in the assessable population, the RECIST v1.0 response rate was 71.6% in the FOLFOXIRI plus bev versus 62.0% in the FOLFIRI plus bev arm (P = 0.043). At the first CT scan evaluation, the median ETS was 31.2% in the FOLFOXIRI plus bev arm, when compared with 23.5% in the control arm (P < 0.001). One hundred forty-one (62.7%) of 225 patients in the FOLFOXIRI plus bev arm achieved an ETS ≥20%, when compared with 112 (51.9%) of 216 patients in the control arm (P = 0.025). The median DoR was 43.4% in the FOLFOXIRI plus bev arm versus 37.8% in the FOLFIRI plus bev arm (P = 0.003). The distribution of DoR in both arms is reported in Figure 2 .
correlation of response measurements with survival parameters
In the overall assessable population, ETS as a continuous variable was significantly associated with PFS (P < 0.001), PPS (P < 0. Table 2) . Baseline variables associated with better long-term outcome were ECOG PS 0, prior adjuvant treatment, left-sided primary, metachronous metastases, disease confined to the liver, resected primary tumor, low Kohne score (supplementary Tables S2 and  S3 , available at Annals of Oncology online). In the multivariate model, stratified for these variables and the treatment arm, ETS was still associated with longer PFS, PPS and OS, both as a continuous and a dichotomous variable ( Table 2) .
The association between ETS and PFS, PPS and OS was evident in both treatment arms and no interaction between ETS and treatment on survival parameters was observed (supplementary Table S4 , available at Annals of Oncology online).
In the overall assessable population, a highly significant association of DoR, both as a continuous and a discrete variable, with PFS, PPS and OS was found (Table 3) . These correlations were highly significant also in the multivariate model. No interaction between DoR and treatment on survival parameters was observed (supplementary Table S5 , available at Annals of Oncology online).
Also RECIST response was significantly associated with survival parameters, both in the univariate and in the multivariate predictive accuracy of response measurements for survival parameters
The predictive accuracy of ETS, DoR and RECIST response for long-term outcome is quantified by C-indices summarized in supplementary Table S8 , available at Annals of Oncology online. All the response measurements are able to accurately predict survival. Achieving an ETS≥ or <20% seems able to predict survival with particularly high accuracy, showing C-indices similar but even higher than RECIST response. In our cohort, a value of ETS equal to 17.3% resulted as the optimal cutoff point for the prediction of long-term OS.
An exploratory attempt to determine the best cutoff value of DoR to optimize the prediction of long-term outcome identified 62.4% as the optimal value to predict OS.
discussion
The present analysis is the first attempt to evaluate the concepts of ETS and DoR, previously assessed in first-line trials with cetuximab, in a phase III study of first-line chemotherapy plus bev.
According to our results, FOLFOXIRI plus bev not only improves the RECIST response rate when compared with FOLFIRI plus bev, but also increases the percentage of patients able to achieve an ETS and enhances DoR.
A highly significant correlation of both ETS and DoR with survival parameters is reported in the assessable population of TRIBE trial and is independent of the treatment arm. The significance of these associations in the multivariate models, adjusted for other prognostic variables, further evidences the strong impact of response measurements on long-term outcome.
The post-hoc analysis of CRYSTAL and OPUS trials suggested not only a prognostic impact for ETS, but also a potential predictive role with regard to the addition of the anti-EGFR cetuximab to a first-line chemotherapy doublet. Recent results from phase III FIRE-3 trial of first-line FOLFIRI plus cetuximab versus FOLFIRI plus bev support this hypothesis. Indeed, while a strong association of ETS with OS was found in both arms, the correlation of ETS with PFS was much more evident among patients treated with FOLFIRI plus cetuximab, thus suggesting that not achieving an ETS ≥20% is a negative predictor of benefit from the anti-EGFR [11] .
Here, we show a significant correlation of ETS with all survival parameters in a cohort of patients treated with chemotherapy plus bev and we show that this association is independent of the intensity of the chemotherapy backbone. The determination in the present analysis of the best cut point of ETS to predict survival lead to pick a cutoff value very close to the 20% cutoff previously identified in first-line trials of chemotherapy plus cetuximab. This confirms the reliability of ETS also as a dichotomous variable, to be easily applied to clinical practice. Test for trend. b Adj hazard ratios refer to the multivariate model stratified for baseline variables significantly associated to survival and adjusted for treatment arm.
*Not including the first 4 months after randomization (landmark). original articles
The prediction performance of ETS with respect to PFS, PPS and OS is at least as good as standard RECIST response, with the advantage of the earlier assessment. Therefore, the use of such an end point in clinical trials would be extremely appealing in order to expedite drug development and potentially orientate therapeutic decisions. Although the surrogacy of ETS at trial level has never been demonstrated up today, an individual patient data analysis of 16 randomized trials included in the ARCAD database recently confirmed a significant prognostic impact of ETS on OS, with an encouraging patient-level prediction accuracy [12] .
Results in terms of DoR emphasize the tumor shrinking ability of FOLFOXIRI plus bev, when compared with FOLFIRI plus bev, thus supporting its adoption as upfront choice whenever a quick and deep response is required. When adopting a doublet as chemotherapy backbone, results from retrospective analyses of RAS wild-type subgroups of patients enrolled in head-to-head trials suggest that anti-EGFR MoAbs may be able to induce earlier and deeper responses than bev [11, 13] . No direct comparison of the triplet plus bev with doublets plus an anti-EGFR MoAb in candidate patients is currently available and present results further strengthen the potential clinical implications of such a prospective comparison. The highly significant correlation of DoR with long-term survival suggests that pursuing tumor shrinkage may be a clinically relevant objective independently from the conversion intent or the urgent need to avoid symptoms' occurrence. In fact, achieving tumor shrinkage positively influences the subsequent steps of patients' history, prolonging their PPS and OS. The association of DoR with OS has been recently evidenced also in the retrospective analysis of the FIRE-3 study and the ability of cetuximab in enhancing the DoR, when compared with bev, has been identified as a potential explanation for the trial's results, showing a significant advantage by FOLFIRI plus cetuximab in terms of OS with no differences in PFS [11] . Here, we clearly show that DoR is highly associated with PFS, as well as PPS and OS, thus evidencing that achieving a deeper response allows not only to prolong survival, but also to delay disease progression.
The potential relevance of DoR as a clinically meaningful end point for clinical trials deserves further investigation. To this purpose and in order to facilitate its adoption in clinical research other than in clinical practice, we tried to identify a cutoff value (62.4%) able to accurately predict long-term outcome. The accuracy of DoR as a dichotomous variable according to this cutoff should be validated in independent cohorts in the next future.
In conclusion, the role of both ETS and DoR as predictors of OS is confirmed for the first time in a chemotherapy plus bev trial. Achieving rapid and deep tumor shrinkage consistently delays tumor progression and prolongs survival, thus supporting the choice of active regimens as upfront treatments independently of the objective of secondary resection.
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